The classification gate that catches longevity brands
NPRA's product classification framework distinguishes Food-Drug Interphase (FDI) products from food and from drugs. A health supplement is defined as a product used to supplement diet and maintain/enhance/improve body function — in capsule, tablet, powder or liquid form, dosed in small unit forms, never sterile (no injectables, no eye drops). The classification breaks toward drug — NPRA jurisdiction — when one of three conditions hits: the product contains an ingredient on the Negative List for FDI; it makes a medicinal/health claim; or it is in a pharmaceutical dosage form (soft gel, capsule, tablet swallowed directly, sublingual, buccal, oral spray).
Examples that automatically classify as drug: products containing paracetamol, glucosamine, tranexamic acid, aspirin, or substances listed under the Poisons Act 1952. Dose-related triggers: plant sterols/stanols/esters at ≥3.5 g/day consumption.
Where NMN, NR and similar longevity actives sit
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are not on NPRA's published Negative List for FDI as of the January 2026 DRGD 11th Revision. That sounds like clearance — it is not. Two operational realities. First, NPRA classifies on a case-by-case basis when an FDI product is submitted for classification (Circular Bil.(97)dlm.BPFK/PPP/01/03 Jld. 2). Second, any "medicinal purpose" claim — defined under Sales of Drug Act 1952 Section 2 — pulls the product into drug regulation regardless of ingredient list.
In practice: a 250mg NMN capsule sold with a maintenance-of-NAD claim is treated as a health supplement and registered via the NPRA health supplement pathway. The same NMN capsule sold with "supports cellular regeneration and aging reversal" language is treated as a drug. The dosage form (capsule, tablet) does not by itself trigger drug status for supplements, but the combination of claim + dosage form raises scrutiny.
Comparing to Singapore and Thailand
Singapore's HSA does not pre-approve health supplements at all — they sit outside the therapeutic products framework unless ingredients appear on the Register of Therapeutic Products. A Singapore NMN capsule simply requires labelling compliance and post-market accountability. Thailand classifies most NMN/NR products as food supplements under the Thai FDA Food Division, requiring registration but with a faster timeline than NPRA's drug pathway.
Malaysia is the strictest of the three on this category. For brand operators planning a SEA launch, the sequence we see working: launch in Singapore first (notification-only), then Thailand (food supplement), then Malaysia (health supplement, drug-side caution). Inverting the order — launching in Malaysia first — adds months of classification correspondence with the NPRA FDI committee.